Dow Up0.00% Nasdaq Up0.09%

Tesaro, Inc. (TSRO)

34.51 Down 0.24(0.69%) Nov 28, 1:00PM EST
ProfileGet Profile for:
Tesaro, Inc.
1000 Winter Street
Suite 3300
Waltham, MA 02451
United States - Map
Phone: 339-970-0900

Index Membership:N/A
Full Time Employees:62

Business Summary 

TESARO, Inc., an oncology-focused biopharmaceutical company, is engaged in the identification, acquisition, development, and commercialization of oncology therapeutics and supportive care product candidates in the United States and internationally. Its product portfolio consist of the Rolapitant, a neurokinin-1 receptor antagonist, which is in Phase 3 oral formulation and Phase 1 intravenous clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an orally active and potent poly polymerase inhibitor that has completed a Phase I clinical trial in cancer patients; and TSR-011, an orally available anaplastic lymphoma kinase inhibitor, which is in Phase 1/2 dose escalation clinical trials in cancer patients. The company was founded in 2010 and is headquartered in Waltham, Massachusetts.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Tesaro, Inc.

Corporate Governance 
Tesaro, Inc.’s ISS Governance QuickScore as of Nov 1, 2014 is 3. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 3; Compensation: 4.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Leon O. Moulder Jr., M.B.A., 57
Co-Founder, Chief Exec. Officer and Director
Dr. Mary Lynne Hedley Ph.D., 51
Co-Founder, Pres, Chief Operating Officer and Director
Mr. Timothy R. Pearson , 46
Chief Financial Officer
Mr. Edward C. English , 47
Principal Accounting Officer, VP and Controller
Ms. Jennifer Davis ,
Sr. Director of Corp. Devel. & Investor Relations
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders